自身免疫性肾小球肾炎中补体途径激活的比较
研究随访112例局灶节段性肾小球硬化、膜性肾病、IgA肾病、狼疮肾炎和抗中性粒细胞胞质抗体相关血管炎患者,中位随访22(12-52)个月,在临床活动度最高时同步检测尿补体标志物。结果显示各途径标志物与蛋白尿严重程度相关,终末途径片段在局灶节段性肾小球硬化和膜性肾病患者中较高,替代途径和经典/凝集途径均独立参与终末途径激活。
要点
- 尿补体各途径标志物与蛋白尿严重程度相关
- 终末途径片段在局灶节段性肾小球硬化和膜性肾病患者中较高
- 替代途径和经典/凝集途径均独立参与终末途径激活
核心结论
- 替代途径和经典/凝集途径分别参与自身免疫性肾小球肾炎的终末途径激活,两者似乎均为有效的潜在治疗靶点。
研究设计与样本
- 随访112例局灶节段性肾小球硬化、膜性肾病、IgA肾病、狼疮肾炎和抗中性粒细胞胞质抗体相关血管炎患者,中位随访22(12-52)个月。
- 在临床活动度最高时同步评估尿C3a、C5a、sC5b-9、MASP-1、MASP-2、C1q、C4a、Ba和Bb。
主要发现
- 各途径尿补体生物标志物均与蛋白尿严重程度相关。
- 终末途径片段在局灶节段性肾小球硬化和膜性肾病患者中高于IgA肾病、狼疮肾炎和抗中性粒细胞胞质抗体相关血管炎患者。
- 替代途径方面,IgA肾病和狼疮肾炎患者尿Ba水平低于局灶节段性肾小球硬化患者。
- 经典/凝集途径方面,各疾病间尿C4a、MASP-1和MASP-2水平相似,而狼疮肾炎患者尿C1q水平较低。
- 每种肾小球肾炎中,替代途径和经典/凝集途径激活标志物与终末途径激活程度存在独立关联,但抗中性粒细胞胞质抗体相关血管炎的替代途径除外,原文称或许因把握度不足。
临床怎么用
- 原文未据此给出推荐;作者认为替代途径和经典/凝集途径似乎均为自身免疫性肾小球肾炎的潜在治疗靶点。
局限性
- 原文在抗中性粒细胞胞质抗体相关血管炎替代途径结果处自述或许因把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies on complement activation have implicated a combination of the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP) in triggering the terminal pathway (TP) for each common autoimmune glomerulonephritis (GN). Evaluating different pathways simultaneously may help identify whether one is preferentially activated and, consequently, which is best to target for each disease. METHODS: We followed 112 patients with focal segmental glomerular sclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy (IgAN), lupus nephritis (LN), and antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) for a median duration of 22 (12-52) months. At the time of greatest clinical activity, we simultaneously evaluated urinary C3a (C3 convertase activity), C5a and sC5b-9 (TP), MASP-1 and MASP-2 (LP), C1q (CP), C4a (CP/LP), and Ba and Bb (AP). We evaluated the relation between activation fragments of the AP and CP/LP with the TP. RESULTS: Urinary complement biomarkers for each pathway were associated with the severity of proteinuria. Fragments of the TP were higher among patients with FSGS and MN compared with patients with IgAN, LN, and AAV. For the AP, urinary Ba level was lower in those with IgAN and LN compared with those with FSGS. For the CP/LP, urinary C4a, MASP-1, and MASP-2 levels were similar between diseases whereas urinary C1q levels were lower in those with LN. For each GN, independent associations existed between the activation markers of the AP and CP/LP with the degree of TP activation, except for the AP in AAV, although perhaps underpowered. CONCLUSION: The AP and CP/LP contribute individually to the TP activation in autoimmune GN, and both seem to be valid potential therapeutic targets.
引用
- Genest DS, Bonnefoy A, Khalili M, et al. Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis. Kidney Int Rep. 2022. PMID: 35571000. doi:10.1016/j.ekir.2022.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。